Name | 6-imidazol-1-yl-7-nitro-1,4-dihydroquinoxaline-2,3-dione,hydrochloride |
---|---|
Synonyms |
N-Acetyltryptamine
C11H7N5O4 YM 90K ym 900 2,3-Quinoxalinedione, 1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-, hydrochloride (1:1) 6-(1H-Imidazol-1-yl)-7-nitro-1,4-dihydro-2,3-quinoxalinedione hydrochloride (1:1) |
Description | YM90K is a potent and selective AMPA receptor antagonist with a Ki of 84 nM. YM90K is less potent in inhibiting kainate (Ki of 2.2 μM) and NMDA (Ki of 37 μM) receptors. YM90K has neuroprotective actions[1]. |
---|---|
Related Catalog | |
Target |
Ki: 84 nM (AMPA receptor), 2.2 μM (Kainate receptor) and 37 μM (NMDA receptor)[1] |
In Vitro | YM90K (30 nmol) co-injected with AMPA or kainate into the rat striatum protected cholinergic neurons against AMPA- or kainate-induced neurotoxicity[1]. |
In Vivo | YM90K showes potent suppressive activity against audiogenic seizure in DBA/2 mice; ED50 values of YM90K against tonic seizure is 2.54 mg/kg (i.p.). The duration of the anticonvulsant effects of YM90K is 30 min[1]. In a global ischemia model, YM90K (15 mg/kg i.p. x 3) significantly prevents the delayed neuronal death in the hippocampal CA1 region in Mongolian gerbils when administered 1 h after 5-min ischemia. The therapeutic time window for the neuroprotective effect of YM90K (30 mg/kg i.p. x 3) is 6 h[1]. In a focal ischemia model, YM90K (30 mg/kg i.v. bolus+10 mg/kg/h for 4 h) reduces the volume of ischemic damage in the cerebral cortex in F344 rats[1]. |
References |
Boiling Point | 556.6ºC at 760mmHg |
---|---|
Molecular Formula | C11H8ClN5O4 |
Molecular Weight | 309.665 |
Flash Point | 290.4ºC |
Exact Mass | 309.026489 |
PSA | 129.36000 |
LogP | 1.63550 |
Index of Refraction | 1.84 |